IL220922B - Methods for producing adenoviral vectors and preparations produced by them - Google Patents

Methods for producing adenoviral vectors and preparations produced by them

Info

Publication number
IL220922B
IL220922B IL220922A IL22092212A IL220922B IL 220922 B IL220922 B IL 220922B IL 220922 A IL220922 A IL 220922A IL 22092212 A IL22092212 A IL 22092212A IL 220922 B IL220922 B IL 220922B
Authority
IL
Israel
Prior art keywords
methods
adenovirus vectors
viral preparations
producing adenovirus
preparations generated
Prior art date
Application number
IL220922A
Other languages
English (en)
Hebrew (he)
Inventor
Breitbart Eyal
Bangio Livnat
Sher Naamit
Original Assignee
Vascular Biogenics Ltd
Breitbart Eyal
Bangio Livnat
Sher Naamit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd, Breitbart Eyal, Bangio Livnat, Sher Naamit filed Critical Vascular Biogenics Ltd
Publication of IL220922B publication Critical patent/IL220922B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL220922A 2010-01-12 2012-07-12 Methods for producing adenoviral vectors and preparations produced by them IL220922B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29415810P 2010-01-12 2010-01-12
PCT/IB2011/050137 WO2011086509A1 (en) 2010-01-12 2011-01-12 Methods of producing adenovirus vectors and viral preparations generated thereby

Publications (1)

Publication Number Publication Date
IL220922B true IL220922B (en) 2019-03-31

Family

ID=43982270

Family Applications (1)

Application Number Title Priority Date Filing Date
IL220922A IL220922B (en) 2010-01-12 2012-07-12 Methods for producing adenoviral vectors and preparations produced by them

Country Status (6)

Country Link
US (2) US20130052165A1 (https=)
EP (1) EP2523681A1 (https=)
JP (1) JP6009357B2 (https=)
IL (1) IL220922B (https=)
SG (2) SG182490A1 (https=)
WO (1) WO2011086509A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
CN100506284C (zh) 2001-10-19 2009-07-01 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
EP2051988A4 (en) 2006-07-31 2010-06-02 Vascular Biogenics Ltd POLYPEPTIDES AND THESE CODING POLYNUCLEOTIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISEASES RELATED TO ISCHEMIA
NZ601324A (en) 2010-01-05 2014-10-31 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
AU2011204407B2 (en) 2010-01-05 2015-05-07 Vascular Biogenics Ltd. Compositions and methods for treating glioblastoma GBM
PL2908865T3 (pl) * 2012-10-17 2019-08-30 Vascular Biogenics Ltd. Adenowirus wykazujący ekspresję chimery Fas i jego zastosowanie w sposobach leczenia raka
CN103012591B (zh) * 2012-12-12 2014-05-14 武汉吉爱生物技术有限公司 抗Benzonase单克隆抗体、其制备方法和应用
EP2951307B1 (en) 2013-02-04 2019-12-25 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
EP2970920B1 (en) * 2013-03-15 2018-04-25 The Children's Hospital of Philadelphia Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system
CN107603956A (zh) * 2017-08-24 2018-01-19 乾元浩生物股份有限公司 一种禽腺病毒纸片载体潮汐式悬浮培养方法
CN107630004B (zh) * 2017-09-01 2021-01-15 康希诺生物股份公司 降低可复制性腺病毒产生的细胞株及构建方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5747340A (en) 1994-06-03 1998-05-05 Syntex (U.S.A.) Inc. Targeted gene expression using preproendothelin-1 promoters
WO1997008298A1 (en) * 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
WO1998022588A2 (en) * 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
NZ512504A (en) * 1998-12-31 2004-01-30 Aventis Pharma Sa Method for separating viral particles
US6168941B1 (en) * 2000-04-07 2001-01-02 Genvec, Inc. Method of producing adenoviral vector stocks
US20070286845A1 (en) * 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2002348151A1 (en) * 2001-11-05 2003-05-19 Genvec, Inc. Viral vector production methods and compositions
US7459154B2 (en) * 2002-12-26 2008-12-02 Cell Genesys, Inc. Methods and reagents for the enhancement of virus transduction in the bladder epithelium
US20090232808A1 (en) * 2005-01-28 2009-09-17 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
EP2051988A4 (en) * 2006-07-31 2010-06-02 Vascular Biogenics Ltd POLYPEPTIDES AND THESE CODING POLYNUCLEOTIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISEASES RELATED TO ISCHEMIA

Also Published As

Publication number Publication date
JP6009357B2 (ja) 2016-10-19
US20130052165A1 (en) 2013-02-28
SG182490A1 (en) 2012-08-30
WO2011086509A1 (en) 2011-07-21
EP2523681A1 (en) 2012-11-21
SG10201500015TA (en) 2015-02-27
US20130295053A1 (en) 2013-11-07
JP2013516978A (ja) 2013-05-16

Similar Documents

Publication Publication Date Title
IL220922B (en) Methods for producing adenoviral vectors and preparations produced by them
ZA201404962B (en) Modified mini-hepcidin peptides and methods of using thereof
ZA201301862B (en) Oncolytic adenoviral vectors and methods and uses related thereof
IL232161B (en) Lyophilized liposomes and methods for their preparation
LT3040424T (lt) Modifikuoti baltymai ir jų gavimo ir panaudojimo būdai
IL221858A (en) Stabilization of viral particles
IL230855A0 (en) Cabazitaxel formulations and methods for their preparation
EP2654726A4 (en) SOLID DISPERSION FORMULATIONS AND METHODS OF USE
HRP20180607T1 (hr) Glikoproteini i rekombinantni vektori cmv
EP2632491A4 (en) ENHANCED TREATMENT AND MONITORING OF CANCER USING RECOMBINANT VECTORS
EP2525817B8 (en) Vaccine vectors and methods of enhancing immune responses
EP2603223A4 (en) ANTITUMOR RECOMBINANT VACCINE AND METHOD FOR PRODUCING THE SAME
IL233481A0 (en) Peptides and methods of using them
PL2525782T3 (pl) Preparaty nanonośników i sposoby ich wytwarzania
PL3210991T3 (pl) Postać krystaliczna lewoizowalerylospiramycyny II oraz preparaty, sposoby wytwarzania i ich zastosowanie
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
ZA201208229B (en) Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
EP2525651A4 (en) NEW CENTROMERE AND METHOD FOR THEIR USE
EP2613200A4 (en) TONER AND MANUFACTURING METHOD THEREFOR
PT2611530T (pt) Aparelho de secagem por pulverização e métodos de utilização do mesmo
GB201115521D0 (en) Colorant-polyesters and methods of producing colorant-polyesters
LT2702159T (lt) Modifikuoto sendai viruso vakcina ir iliustratyvus vektorius
EP2421542A4 (en) SPUME VIRUS VECTORS AND METHODS OF USE
EP2558117A4 (en) EXPRESSION OF POSITIVELY SENSING INTRODUCING RNA VIRUSES AND USES THEREOF
GB201005520D0 (en) Stabilisation of viral particles

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed